Publications by authors named "Charles Linker"

Claim this Profile
L
Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma.
Sarah A Holstein, Vera J Suman, Kouros Owzar, Katelyn Santo, Don M Benson, Charles Linker

Biol Blood Marrow Transplant· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial.
Sarah A Holstein, Sin-Ho Jung, Paul G Richardson, Craig C Hofmeister, David D Hurd, Charles Linker

Lancet Haematol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502.
Steven M Devine, Kouros Owzar, William Blum, Flora Mulkey, Richard M Stone, Charles Linker

J Clin Oncol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.
Gabriel N Mannis, Charalambos Andreadis, Aaron C Logan, Lloyd E Damon, Leslie Z Benet, Charles A Linker

Clin Lymphoma Myeloma Leuk· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103).
Jan H Beumer, Kouros Owzar, Lionel D Lewis, Chen Jiang, Julianne L Holleran, Charles Linker

Cancer Chemother Pharmacol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance).
Meir Wetzler, Dorothy Watson, Wendy Stock, Gregory Koval, Flora A Mulkey, Charles A Linker

Haematologica· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303.
Carolyn A Keever-Taylor, Steven M Devine, Robert J Soiffer, Adam Mendizabal, Shelly Carter, Charles Linker

Biol Blood Marrow Transplant· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide after stem-cell transplantation for multiple myeloma.
Philip L McCarthy, Kouros Owzar, Craig C Hofmeister, David D Hurd, Hani Hassoun, Charles Linker

N Engl J Med· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909.
Hongtao Liu, Jeffrey L Johnson, Greg Koval, Greg Malnassy, Dorie Sher, Charles A Linker

Haematologica· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901.
Thomas Shea, Jeffrey Johnson, Peter Westervelt, Sherif Farag, John McCarty, Charles Linker

Biol Blood Marrow Transplant· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303.
Steven M Devine, Shelly Carter, Robert J Soiffer, Marcelo C Pasquini, Parameswaran N Hari, Charles Linker

Biol Blood Marrow Transplant· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for patients with hematologic malignancies who relapse following autologous transplantation: a multi-institutional prospective study from the Cancer and Leukemia Group B (CALGB trial 100002).
Asad Bashey, Kouros Owzar, Jeffrey L Johnson, Peggy S Edwards, Michael Kelly, Charles Linker

Biol Blood Marrow Transplant· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.
Lloyd E Damon, Jeffrey L Johnson, Donna Niedzwiecki, Bruce D Cheson, David D Hurd, Charles A Linker

J Clin Oncol· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma.
Sara Gonias, Robert Goldsby, Katherine K Matthay, Randall Hawkins, David Price, Charles Linker

J Clin Oncol· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML).
Ivan M Borrello, Hyam I Levitsky, Wendy Stock, Dorie Sher, Lu Qin, Charles A Linker

Blood· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804.
Richard M Stone, Kathleen A Donohue, Wendy Stock, Vera Hars, Charles A Linker

Cancer Chemother Pharmacol· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease.
Margaret L Macmillan, Daniel Couriel, Daniel J Weisdorf, Gisela Schwab, Nancy Havrilla, Charles Linker

Blood· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of autologous transplantation for acute myeloid leukemia in first and second remission.
Charles Linker

Best Pract Res Clin Haematol· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).
Paul A Fitzgerald, Robert E Goldsby, John P Huberty, David C Price, Randall A Hawkins, Charles A Linker

Ann N Y Acad Sci· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study.
Brian I Rini, Susan Halabi, Robert Barrier, Kim A Margolin, David Avigan, Charles A Linker

Biol Blood Marrow Transplant· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cancer and leukemia group B transplant committee.
Charles Linker, David Hurd

Clin Cancer Res· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.
Lloyd Damon, Hope Rugo, Sara Tolaney, Willis Navarro, Thomas Martin, Charles Linker

Biol Blood Marrow Transplant· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission.
Martin S Tallman, Waleska S Pérez, Hillard M Lazarus, Robert Peter Gale, Richard T Maziarz, Charles Linker

Biol Blood Marrow Transplant· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dose etoposide, thiotepa, and dose-adjusted carboplatin (TVCa) with autologous hematopoietic stem cell rescue as treatment of relapsed or refractory germ cell cancer.
Uzair B Chaudhary, Lloyd E Damon, Hope S Rugo, Charles A Linker, Willis Navarro

Am J Clin Oncol· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule.
Lloyd E Damon, Laura J Johnston, Curt A Ries, Hope S Rugo, Delvyn Case, Charles A Linker

Cancer Chemother Pharmacol· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis